Juxtacapillary (Membranous) Glomerulonephritis
Overview
Juxtacapillary glomerulonephritis, more commonly known as membranous glomerulonephritis (MGN), is a kidney disease characterized by immune‑complex deposition on the outer (subepithelial) side of the glomerular basement membrane. This thickening impairs the kidney’s ability to filter waste and excess fluid, leading to protein loss in the urine and, over time, possible kidney failure.
- Typical age: Adults 30–60 years; rare in children.
- Sex distribution: Slight male predominance (≈55 % male).
- Prevalence: MGN accounts for about 20 % of idiopathic nephrotic syndrome in white adults and up to 30 % of primary glomerular disease worldwide (≈1–2 cases per 100,000 persons per year)【source1】.
Symptoms
The presentation can range from silent (detected on routine labs) to full‑blown nephrotic syndrome. Common symptoms include:
Nephrotic‑Syndrome Manifestations
- Proteinuria: >3.5 g/24 h (often >5 g). Causes frothy or “spume‑like” urine.
- Hypoalbuminemia: Serum albumin < 3 g/dL, leading to swelling.
- Edema: Periorbital puffiness in the morning, ankle/leg swelling, and sometimes abdominal (ascites) or pleural effusions.
- Hyperlipidemia: Elevated cholesterol and triglycerides, which may cause xanthomas.
Other Renal‑Related Symptoms
- Hematuria (microscopic or occasional gross blood).
- Reduced urine output (oliguria) in later stages.
- Hypertension (present in ~30 % of patients).
Systemic / General Symptoms
- Fatigue and generalized weakness.
- Unintended weight gain from fluid retention.
- Pruritus (itching) due to high serum lipids.
Causes and Risk Factors
MGN can be primary (idiopathic) or secondary to another condition.
Primary (Idiopathic) MGN
- Autoimmune response targeting the phospholipase A₂ receptor (PLA₂R) on podocytes – the most common cause (≈70‑80 % of primary cases)【source2】.
- Antibodies against thrombospondin type‑1 domain‑containing 7A (THSD7A) – present in 2‑5 % of primary cases.
Secondary MGN
- Infections: Hepatitis B, hepatitis C, HIV, syphilis, malaria.
- Medications & toxins: Non‑steroidal anti‑inflammatory drugs (NSAIDs), gold salts, penicillamine, interferon, bisphosphonates.
- Autoimmune diseases: Systemic lupus erythematosus (lupus), rheumatoid arthritis, sarcoidosis.
- Cancers: Solid tumors (lung, colon, breast) and hematologic malignancies (lymphoma, leukemia).
- Other conditions: Diabetes mellitus (rarely), thyroid disease.
Risk Factors
- Genetic susceptibility – HLA‑DQ alleles linked to anti‑PLA₂R antibody production.
- Male sex (modest increase).
- Exposure to known offending drugs.
- Chronic viral infections.
Diagnosis
Diagnosing MGN combines clinical assessment, laboratory studies, imaging, and a kidney biopsy.
Initial Laboratory Evaluation
- Urinalysis: Heavy proteinuria, possible microscopic hematuria.
- 24‑hour urine protein: Quantifies protein loss.
- Serum albumin & lipid panel: Detects hypoalbuminemia & hyperlipidemia.
- Renal function: Serum creatinine, estimated GFR.
- Serologic screens: Hepatitis B/C, HIV, ANA, anti‑dsDNA, complement levels to rule out secondary causes.
- PLA₂R & THSD7A antibodies: Positive serum testing supports primary MGN and can guide treatment monitoring【source2】.
Imaging
- Renal ultrasound – assesses kidney size, rules out obstruction.
- Chest X‑ray or CT – performed when a malignancy is suspected.
Kidney Biopsy – Gold Standard
A percutaneous biopsy provides definitive diagnosis:
- Light microscopy: Thickened glomerular basement membrane with “spike” formation on silver stain.
- Immunofluorescence: Granular IgG (predominantly IgG4) and C3 deposition along the capillary wall.
- Electron microscopy: Subepithelial immune‑complex deposits.
Staging (Stage I‑IV) is based on the extent of spikes, thickening, and sclerosis, which helps predict prognosis.
Treatment Options
Treatment is individualized according to disease activity, kidney function, and whether the disease is primary or secondary.
General Measures (All Patients)
- Control blood pressure – ACE inhibitors or ARBs are first‑line; they reduce proteinuria and protect renal function.
- Low‑sodium diet (≤2 g/day) and fluid restriction if edema is severe.
- Statin therapy for hyperlipidemia (LDL < 100 mg/dL recommended).
- Smoking cessation and weight management.
Immunosuppressive Therapy
Reserved for patients with persistent proteinuria >4 g/day, declining GFR, or high anti‑PLA₂R titers.
First‑Line Regimens (2023 KDIGO guidelines)
- Rituximab: Anti‑CD20 monoclonal antibody; 375 mg/m² weekly ×4 or 1 g on days 1 and 15. Achieves remission in ~70 % of primary MGN with fewer side effects than cyclophosphamide【source3】.
- Cyclosporine (calcineurin inhibitor): 3‑5 mg/kg/day targeting trough levels 100‑150 ng/mL; effective but nephrotoxic with long‑term use.
Alternative/Adjunct Options
- Cyclophosphamide + corticosteroids: Ponticelli regimen (alternating months of steroids and alkylating agent) – high remission but higher infection risk.
- Mycophenolate mofetil (MMF):** 1‑2 g/day; modest efficacy, often used when cyclophosphamide is contraindicated.
- Adrenocorticotropic hormone (ACTH) gel: FDA‑approved for nephrotic syndrome; works through melanocortin receptors.
Treatment of Secondary MGN
- Address underlying cause: antiviral therapy for hepatitis, stop offending drug, treat malignancy, or manage systemic autoimmune disease.
- Immunosuppression may still be needed if proteinuria persists after the trigger is removed.
Supportive & Symptomatic Care
- Diuretics (e.g., furosemide) for edema.
- Anticoagulation if serum albumin <2.0 g/dL or VTE history (low‑dose aspirin or warfarin as per guidelines).
- Vaccinations – hepatitis B, pneumococcal, influenza – especially before initiating immunosuppression.
Living with Juxtacapillary (Membranous) Glomerulonephritis
Managing MGN is a partnership between you, your nephrologist, and the broader care team.
Daily Management Tips
- Monitor weight: A sudden gain of >2 kg in a day may signal fluid retention; alert your doctor.
- Track urine: Observe for frothy appearance; keep a urine‑protein log if possible.
- Adhere to medication schedule: Set alarms or use pill organizers for ACE‑I/ARB, immunosuppressants, and diuretics.
- Dietary guidance:
- Limit salt to <2 g/day.
- Maintain protein intake at 0.8‑1 g/kg/day (avoid excessive restriction that can worsen malnutrition).
- Choose heart‑healthy fats (olive oil, nuts) and high‑fiber carbs.
- Physical activity: Moderate aerobic exercise 150 min/week improves cardiovascular health without overloading kidneys.
- Regular labs: Every 3‑6 months—creatinine, eGFR, albumin, lipid panel, and anti‑PLA₂R if applicable.
- Infection vigilance: Promptly report fever, cough, or urinary symptoms; immunosuppressed patients are susceptible.
Psychosocial Aspects
- Join kidney‑disease support groups (online or local).
- Consider counseling for anxiety or depression that can accompany chronic illness.
- Workplace accommodations: discuss flexible schedules if frequent labs or fatigue are issues.
Prevention
Because many cases are idiopathic, primary prevention is limited, but steps can reduce secondary risk:
- Vaccinate against hepatitis B and C; practice safe sex and avoid needle sharing.
- Use NSAIDs and other nephrotoxic drugs sparingly; discuss alternatives with your physician.
- Maintain good control of chronic infections and autoimmune conditions.
- Screen for and treat malignancies early, especially in high‑risk populations (smokers, family history).
Complications
If left untreated or poorly controlled, MGN can lead to serious outcomes:
- Chronic kidney disease (CKD) progression: Up to 30 % develop end‑stage renal disease (ESRD) within 10–15 years.
- Thromboembolic events: Nephrotic syndrome increases risk of deep‑vein thrombosis and pulmonary embolism.
- Infections: Immunosuppression plus low‑protein immunity predisposes to bacterial, viral, and fungal infections.
- Cardiovascular disease: Hyperlipidemia and hypertension accelerate atherosclerosis.
- Malignancy: Secondary MGN may be a paraneoplastic marker; persistent disease prompts cancer surveillance.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
```
- Sudden, severe swelling of the face, lips, or throat (possible angioedema from medication reaction).
- Rapid onset of shortness of breath or chest pain – could signal pulmonary embolism or severe fluid overload.
- Dark, cola‑colored urine or a sudden increase in visible blood in the urine.
- Fever > 38.5 °C (101.3 °F) with chills, especially if you are on immunosuppressive therapy.
- Severe abdominal pain with vomiting – may indicate a complication such as a renal vein thrombosis.
- Unexplained sudden drop in urine output (less than 400 mL per 24 h) accompanied by swelling.
These signs require immediate medical evaluation to prevent life‑threatening complications.